Olivier Legrain, Chief Executive Officer of IBA commented: "Many studies have demonstrated that innovation is best achieved by creating an environment where ideas are shared openly to foster collaboration between partners. This is deeply rooted in IBA's culture and has been consistently proven by our history of leading innovation in proton therapy over the last 20 years. We will continue to share knowledge and expertise with the best experts in the world to make proton therapy available and affordable to all patients who could benefit from it."
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com
1 Arc Therapy and Flash Therapy are currently under research and development phase and will be available for sale when regulatory clearance is received.
2 This program benefited from a financial support of Wallonia in the frame of a program initiated by the BioWin and Mecatech clusters
Back to HCB News
